A fluorescent probe DH1 has been successfully developed to detect HSA via site I non-covalent bonding. DH1 shows a dramatic fluorescence enhancement towards HSA without interference from other proteins. The molecular docking method, for the first time, was utilized to provide deep insight into the sensing mechanism of the probe. Moreover, probe DH1 was successfully used to detect trace HSA in healthy human urine.

The “molecular machine” C34 could suppress tumor systemically via unimolecule-mediated sono/immunotherapy.

A simple and stability-indicating reverse phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for the determination of olanzapine (OLN) and related impurities in bulk drugs. Eight impurities were characterized respectively, and particularly a new process impurity from OLN synthesis was structurally confirmed as 1-(5-methylthionphen-2-yl)-1H-benzimidazol-2(3H)-one (Imp-7) by X-ray single crystal diffraction, MS, ¹H NMR, ¹³C NMR and HSQC. A mechanism of formation pathway for Imp-7 was proposed. Optimum separation for OLN and eight related impurities was carried out on an Agilent Octyldecyl silica column (TC-C₁₈, 4.6 mm × 250 mm, 5 μm) using a gradient HPLC method. The method was validated with respect to specificity, linearity, accuracy, precision, LOD and LOQ. Regression analysis showed good correlation (r² > 0.9985) between the investigated component concentrations and their peak areas within the test ranges for OLN and eight impurities. The repeatability and intermediate precision, expressed as RSD, were less than 1.74%. The proposed stability-indicating method was suitable for routine quality control and drug analysis of OLN in bulk drugs.